Search for: [Abstract = "the risk of depressive symptoms. In patients with MPN, a common predictor of the severity of somatization symptoms \(B = 0.760\; p = <0.001\), anxiety \(B = 0.749\; p = <0.001\), and depressive symptoms \(B = 0.635\; p = <0.001\) was the number of side effects. Additionally, age was an important prognostic factor for anxiety symptoms \(B = \-0.082\; p = <0.046\), and female gender was a significant prognostic factor for depressive symptoms \(B = \-1.377\; p = <0.043\). The study showed that individual side effects of IFN\- treatment have an impact on the increase of anxiety, somatization, and depressive symptoms, as well as anxiety symptoms in patients treated with IKT. Conclusions\: The collected data on patients with myeloproliferative neoplasms who have suffered from mental and physical symptoms of the disease, or its treatment justifies the need for caring psychological, psychiatric, and educational care. The collaborative work of physicians, psychologists, and pharmaceutical companies on reducing\/alleviating side effects may establish a better quality of life for these patients in the future. In the future, it would be recommended to monitor the mental condition of patients suffering from disorders of the hematopoietic system through a preliminary survey of newly diagnosed patients and then periodically conduct similar tests during their treatment. If depression"]
